# Meeting 19 æº–å‚™ç­†è¨˜

> **å»ºç«‹æ—¥æœŸ**ï¼š2026-01-07
> **ç‹€æ…‹**ï¼šæº–å‚™ä¸­

---

## MJ Health è³‡æ–™ç”³è«‹èª¿æŸ¥

### è¯ç¹«è³‡è¨Š

| é …ç›® | å…§å®¹ |
|------|------|
| **Email** | contact_us@mjhrf.org |
| **ç¶²ç«™** | http://www.mjhrf.org/ |
| **è¯ç¹«é é¢** | http://www.mjhrf.org/en/index.php?action=contact |
| **åœ°å€** | å°åŒ—å¸‚å…§æ¹–å€è¡Œå–„è·¯58è™Ÿ3æ¨“ä¹‹3 (114066) |

### è³‡æ–™åº«é¡å‹

æˆ‘å€‘éœ€è¦çš„æ˜¯**å¥åº·æ•¸æ“šè³‡æ–™åº«**ï¼ˆéç”Ÿç‰©è³‡æ–™åº«ï¼‰ï¼š

1. **ç¾å…†å¥åº·å•å·è³‡æ–™åº«**
   - 5å¤§é¡ã€è¶…é100é¡Œ
   - å…§å®¹ï¼šåŸºæœ¬è³‡æ–™ã€å€‹äººåŠå®¶æ—ç—…å²ã€è¿‘æ³èª¿æŸ¥ã€ç”Ÿæ´»ç¿’æ…£ã€é£²é£Ÿç¿’æ…£
   - è‡ª 1996 å¹´èµ·ç´¯ç©

2. **ç¾å…†ç”ŸåŒ–æª¢æŸ¥è³‡æ–™åº«**
   - 100é¤˜é …å¥æª¢é …ç›®
   - å…§å®¹ï¼šèº«é«”æ¸¬é‡ã€è¡€æ¶²æª¢é©—ã€è¡€ç³–ã€è¡€è„‚ã€è‚åŠŸèƒ½ã€è…åŠŸèƒ½ã€è‚ºåŠŸèƒ½ç­‰
   - 1994 å¹´èµ·é›»å­åŒ–
   - å¯èˆ‡å•å·è³‡æ–™åº«ä¸²é€£åˆ†æ

### ç”³è«‹é ˆçŸ¥é‡é»

| é …ç›® | å…§å®¹ |
|------|------|
| **ç”³è«‹è³‡æ ¼** | æ©Ÿæ§‹åç¾©ï¼ˆä¸æ¥å—å€‹äººï¼‰ |
| **ç”³è«‹æ–‡ä»¶** | ã€Œç¾å…†å¥åº·è³‡æºä¸­å¿ƒè³‡æ–™ç”³è«‹æ›¸ã€ |
| **å¯©æŸ¥æµç¨‹** | æ›¸é¢å¯©æŸ¥ï¼ˆå¥åº·æ•¸æ“šä¸éœ€ IRBï¼‰ |
| **ç°½ç´„æ–‡ä»¶** | ã€ŒMJå¥åº·æ•¸æ“šè³‡æ–™ä½¿ç”¨åŒæ„æ›¸ã€ |
| **è³‡æ–™å½¢å¼** | å»è­˜åˆ¥åŒ–ï¼Œå…‰ç¢Ÿæˆ–åŠ å¯†é€£çµ |
| **ä½¿ç”¨æœŸé™** | 2 å¹´ï¼Œå¯å±•å»¶åŠå¹´ |
| **è®Šé …ä¸Šé™** | 200 å€‹ï¼ˆå¥åº·æ•¸æ“š 70 + å•å· 130ï¼‰ |
| **ç™¼è¡¨è¦æ±‚** | éœ€è¨»æ˜è³‡æ–™ä¾†æº |

### æ”¶è²»æ¨™æº–ï¼ˆ2025/01/01 ç‰ˆï¼‰

#### ä¸€èˆ¬ç”³è«‹æ¡ˆ vs ç”¢æ¥­ç”³è«‹æ¡ˆ

| é …ç›® | ä¸€èˆ¬ç”³è«‹æ¡ˆï¼ˆå­¸è¡“ï¼‰ | ç”¢æ¥­ç”³è«‹æ¡ˆ |
|------|-------------|---------|
| **è³‡æ–™è™•ç†è²»** | 15,000 å…ƒ | 37,500 å…ƒ |
| **è³‡æ–™è²» â‰¤150è¬é»** | 35,000 å…ƒ | 87,500 å…ƒ |
| **è³‡æ–™è²» 500~1000è¬é»** | 70,001~120,000 å…ƒ | 175,001~300,000 å…ƒ |

> å­¸è¡“å–®ä½è²»ç”¨ç´„ç‚ºç”¢æ¥­çš„ **40%**

#### è³‡æ–™è²»å±¤ç´šè¡¨ï¼ˆä¸€èˆ¬ç”³è«‹æ¡ˆï¼‰

| æœ‰æ•ˆè³‡æ–™é»æ•¸ | è²»ç”¨ (å°å¹£) |
|---------|------|
| â‰¤150 è¬é» | 35,000 å…ƒ |
| 150~250 è¬é» | 35,001~45,000 å…ƒ |
| 250~500 è¬é» | 45,001~70,000 å…ƒ |
| 500~1,000 è¬é» | 70,001~120,000 å…ƒ |
| 1,000~2,000 è¬é» | 120,001~230,000 å…ƒ |
| 2,000~5,000 è¬é» | 230,001~350,000 å…ƒ |

> **æœ‰æ•ˆè³‡æ–™é»æ•¸** = æ¨£æœ¬æ•¸ Ã— è®Šé …æ•¸ âˆ’ éºæ¼å€¼

#### è²»ç”¨ä¼°ç®—ç¯„ä¾‹

å‡è¨­é¡ä¼¼ Taiwan MJ è«–æ–‡è¦æ¨¡ï¼š
- æ¨£æœ¬æ•¸ï¼š~50,000 äºº
- è®Šé …æ•¸ï¼š~50 å€‹
- å¥æª¢æ¬¡æ•¸ï¼š3 æ¬¡
- æœ‰æ•ˆè³‡æ–™é»æ•¸ï¼š50,000 Ã— 50 Ã— 3 = **750 è¬é»**

| é …ç›® | è²»ç”¨ |
|------|------|
| è³‡æ–™è™•ç†è²» | 15,000 å…ƒ |
| è³‡æ–™è²»ï¼ˆ500~1000è¬é»ï¼‰ | ~95,000 å…ƒ |
| **é ä¼°ç¸½è¨ˆ** | **~110,000 å…ƒ** |

### çµè«–

- è²»ç”¨åˆç†ï¼ˆå­¸è¡“ç´„ 10~15 è¬å°å¹£ï¼‰
- éœ€ä»¥**æ©Ÿæ§‹åç¾©**ç”³è«‹
- æµç¨‹æ¯”ç”Ÿç‰©è³‡æ–™åº«ç°¡å–®ï¼ˆä¸éœ€ IRBï¼‰
- è©³ç´°è³‡è¨Šå¯åƒè€ƒå®˜ç¶²

### åƒè€ƒæ–‡ä»¶

- æ”¶è²»æ¨™æº– PDFï¼š[data/MJ/æ”¶è²»æ¨™æº–-å¥åº·æ•¸æ“šè³‡æ–™åº«20250101.pdf](../../data/MJ/æ”¶è²»æ¨™æº–-å¥åº·æ•¸æ“šè³‡æ–™åº«20250101.pdf)
- å®˜ç¶²ï¼šhttp://www.mjhrf.org/

---

## Meeting 19 å¾…è¾¦äº‹é …ï¼ˆå¾ Meeting 18 å»¶çºŒï¼‰

### è¡Œæ”¿/ç ”ç©¶æ–¹å‘
- [x] è¯ç¹« MJ Health - å·²èª¿æŸ¥ç”³è«‹æµç¨‹èˆ‡è²»ç”¨
- [ ] æ’°å¯« Problem Definitionï¼ˆå«æ•¸å­¸å…¬å¼ï¼‰
- [x] é¸è®€ä¸€ç¯‡ç›¸é—œè«–æ–‡ï¼ˆå·²å»ºç«‹ SMOTE+SHAP / Prediabetes 2024 memoï¼‰
- [ ] æ•´ç†å¯¦é©—/å‡èªªåˆ—è¡¨

### å¯¦é©—ä»»å‹™
- [ ] Decision Tree (DT) æ¨¡å‹
- [ ] MTL vs STL å®Œæ•´æ¯”è¼ƒ
- [ ] PySR åƒæ•¸èª¿æ•´å¯¦é©—ï¼ˆå…ˆèª¿åƒï¼Œå†åš 5-fold CVï¼‰
- [ ] PySR æ¨¹æ·±åº¦å¯¦é©—
- [ ] å¥æª¢æ¬¡æ•¸èˆ‡é æ¸¬æº–ç¢ºåº¦ï¼ˆå¯é¸ï¼‰

### å¾…è™•ç†å‚™å¿˜
- **PySR 5-fold CV**ï¼šç›®å‰åƒæ•¸ï¼ˆniterations=100, timeout=300ï¼‰æœƒå°è‡´ AUC=0.5ï¼ˆå¸¸æ•¸è§£ï¼‰
  - éœ€è¦å…ˆç”¨ notebook 12 çš„åƒæ•¸åšèª¿æ•´å¯¦é©—
  - ç¢ºèªæœ€ä½³åƒæ•¸å¾Œå†åŸ·è¡Œ 5-fold CV
  - åƒè€ƒæˆåŠŸè¨­å®šï¼šniterations=200, timeout=1200, maxsize=25

### å¿…åš
- [x] 5-fold CVï¼ˆæ‰€æœ‰æ¨¡å‹ï¼‰âœ… 2026-01-07 å®Œæˆ

---

## 5-Fold CV å¯¦é©—çµæœ

### å¯¦é©—è¨­è¨ˆ
- **äº¤å‰é©—è­‰**ï¼š5-Fold Stratified CV
- **æ¨¡å‹**ï¼šLR, DT, RF, XGB, SVM, NNï¼ˆå…± 6 å€‹ï¼‰
- **ç–¾ç—…**ï¼šHypertension, Hyperglycemia, Dyslipidemia
- **è©•ä¼°æŒ‡æ¨™**ï¼šAUC, Sensitivity, Specificity, F1, Balanced Accuracy

### AUC çµæœæ‘˜è¦ï¼ˆmean Â± stdï¼‰

| Disease | LR | DT | RF | XGB | SVM | NN |
|---------|-----|-----|-----|-----|-----|-----|
| **Hypertension** | 0.754 (0.014) | 0.678 (0.022) | **0.791** (0.018) | 0.789 (0.018) | 0.776 (0.020) | 0.733 (0.065) |
| **Hyperglycemia** | **0.932** (0.006) | 0.817 (0.018) | 0.930 (0.008) | 0.918 (0.010) | 0.915 (0.006) | 0.917 (0.011) |
| **Dyslipidemia** | **0.867** (0.017) | 0.720 (0.022) | 0.857 (0.017) | 0.857 (0.015) | 0.845 (0.022) | 0.479 (0.176) |

### é—œéµç™¼ç¾

1. **å„ç–¾ç—…æœ€ä½³æ¨¡å‹**
   - Hypertension: **RF** (0.791) â‰ˆ XGB (0.789)
   - Hyperglycemia: **LR** (0.932) â‰ˆ RF (0.930)
   - Dyslipidemia: **LR** (0.867)

2. **LR è¡¨ç¾äº®çœ¼**
   - Hyperglycemia å’Œ Dyslipidemia ä¸Šéƒ½æ˜¯æœ€ä½³æˆ–æ¥è¿‘æœ€ä½³
   - æ¨™æº–å·®å°ã€ç©©å®šæ€§é«˜
   - å…·å‚™å®Œæ•´å¯è§£é‡‹æ€§ â†’ é©åˆè‡¨åºŠæ‡‰ç”¨

3. **NN ä¸ç©©å®š**
   - Dyslipidemia ä¸Š AUC åªæœ‰ 0.479ï¼ˆæ¯”éš¨æ©Ÿé‚„å·®ï¼‰
   - æ¨™æº–å·®å¾ˆå¤§ (0.176)ï¼Œå¯èƒ½éœ€è¦èª¿åƒæˆ–æ›´å¤šè³‡æ–™

4. **DT è¡¨ç¾è¼ƒå·®**
   - åœ¨æ‰€æœ‰ç–¾ç—…ä¸Š AUC éƒ½æœ€ä½
   - ä½†ä»å¯æä¾›æ±ºç­–è¦å‰‡çš„å¯è§£é‡‹æ€§

### çµè«–

**Logistic Regression æ˜¯æœ€ä½³é¸æ“‡**ï¼š
- æ•ˆèƒ½å¥½ï¼ˆHyperglycemia AUC=0.932ï¼‰
- ç©©å®šï¼ˆstd æœ€å°ï¼‰
- å®Œå…¨å¯è§£é‡‹ï¼ˆä¿‚æ•¸å¯ç›´æ¥è½‰æ›ç‚º Odds Ratioï¼‰

### è¼¸å‡ºæª”æ¡ˆ
- [5fold_cv_model_comparison.csv](../../results/5fold_cv_model_comparison.csv)
- [5fold_cv_summary_table.csv](../../results/5fold_cv_summary_table.csv)
- [5fold_cv_auc_comparison.png](../../results/5fold_cv_auc_comparison.png)
- [5fold_cv_roc_curves.png](../../results/5fold_cv_roc_curves.png)
- [5fold_cv_metrics_heatmap.png](../../results/5fold_cv_metrics_heatmap.png)

---

## Meeting 19 è«–æ–‡é¸è®€ï¼šKanegae Hypertension 2020 â­

> **é¸æ“‡ç†ç”±**ï¼šé€™ç¯‡è«–æ–‡ä½¿ç”¨ã€Œç¸±å‘è®ŠåŒ–é‡ç‰¹å¾µã€ï¼ˆYear(-2) â†’ Year(-1) â†’ Year(0)ï¼‰ï¼Œèˆ‡æˆ‘å€‘çš„ T1 â†’ T2 â†’ T3 + Delta è¨­è¨ˆå¹¾ä¹ä¸€è‡´ï¼Œæ˜¯ç›®å‰æ‰¾åˆ°æœ€èƒ½é©—è­‰æˆ‘å€‘æ–¹æ³•è«–çš„åƒè€ƒæ–‡ç»ï¼

### è«–æ–‡åŸºæœ¬è³‡è¨Š

| é …ç›® | å…§å®¹ |
|------|------|
| **æ¨™é¡Œ** | Highly precise risk prediction model for new-onset hypertension using artificial intelligence techniques |
| **æœŸåˆŠ** | The Journal of Clinical Hypertension (2020) |
| **DOI** | [10.1111/jch.13759](https://doi.org/10.1111/jch.13759) |
| **è©³ç´°ç­†è¨˜** | [Paper_Kanegae_Hypertension_2020.md](../02_literature/summaries/Paper_Kanegae_Hypertension_2020.md) |
| **ä¸­æ–‡ç¿»è­¯** | [Kanegae_Hypertension_2020_ä¸­æ–‡ç¿»è­¯.md](../02_literature/translations/Kanegae_Hypertension_2020_ä¸­æ–‡ç¿»è­¯.md) |

---

## ğŸ“Š ç°¡å ±å¤§ç¶±

### ç¬¬ 1 é ï¼šæ¨™é¡Œé 

**Highly precise risk prediction model for new-onset hypertension using artificial intelligence techniques**

- The Journal of Clinical Hypertension, 2020
- Kanegae et al. (æ—¥æœ¬)

---

### ç¬¬ 2 é ï¼šç‚ºä»€éº¼é¸é€™ç¯‡ï¼Ÿâ€” èˆ‡æˆ‘å€‘ç ”ç©¶çš„é«˜åº¦ç›¸ä¼¼æ€§

| é …ç›® | Kanegae 2020 | æˆ‘å€‘çš„ç ”ç©¶ |
|------|-------------|-----------|
| **ç¸±å‘è¨­è¨ˆ** | Year(-2) â†’ Year(-1) â†’ Year(0) | T1 â†’ T2 â†’ T3 |
| **Î” è®ŠåŒ–é‡ç‰¹å¾µ** | âœ… Changes from Year(-2) to Year(-1) | âœ… Delta1 = T2 - T1 |
| **è¿½è¹¤æœŸé–“** | 2 å¹´å¥æª¢ç´€éŒ„ | ç´„ 4 å¹´ï¼ˆT1-T3ï¼‰ |
| **æ¨£æœ¬æ•¸** | 18,258 | ~6,000 (HRS) |
| **ML æ¨¡å‹** | XGBoost, Ensemble, LR | LR, RF, XGB, SVM, MLP, DT, PySR |
| **å¤–éƒ¨é©—è­‰** | âŒ | âœ… (CLSA) |

**â†’ é€™ç¯‡è«–æ–‡é©—è­‰äº†æˆ‘å€‘ä½¿ç”¨ã€Œç¸±å‘è®ŠåŒ–é‡ç‰¹å¾µã€çš„æ–¹æ³•è«–æ˜¯æœ‰æ•ˆçš„ï¼**

---

### ç¬¬ 3 é ï¼šç ”ç©¶è¨­è¨ˆ

**è³‡æ–™ä¾†æº**ï¼š
- 2005-2016 å¹´æ—¥æœ¬è·å ´å¥åº·æª¢æŸ¥æ•¸æ“š
- n = 18,258ï¼ˆæ­£å¸¸è¡€å£“è€…ï¼Œè¿½è¹¤è‡³é«˜è¡€å£“ç™¼ç”Ÿï¼‰

**æ™‚é–“æ¶æ§‹ â­**ï¼š
```
Year(-2)     Year(-1)     Year(0)
   â”‚            â”‚            â”‚
   â””â”€â”€â”€â”€ Î” â”€â”€â”€â”€â”€â”˜            â”‚
         â”‚                   â”‚
    è®ŠåŒ–é‡ç‰¹å¾µ          é æ¸¬ç›®æ¨™ï¼šæ˜¯å¦é«˜è¡€å£“
```

**ç‰¹å¾µé¡å‹**ï¼š
1. Year(-2) æ¸¬é‡å€¼
2. Year(-1) æ¸¬é‡å€¼
3. **Î” è®ŠåŒ–é‡ = Year(-1) âˆ’ Year(-2)** â† æ ¸å¿ƒå‰µæ–°

---

### ç¬¬ 4 é ï¼šæ–¹æ³•è«–

**æ¨¡å‹æ¯”è¼ƒ**ï¼š

| æ¨¡å‹ | é¡å‹ |
|------|------|
| XGBoost | æ©Ÿå™¨å­¸ç¿’ |
| Ensemble | æ©Ÿå™¨å­¸ç¿’ï¼ˆå¤šæ¨¡å‹é›†æˆï¼‰ |
| Logistic Regression | å‚³çµ±çµ±è¨ˆï¼ˆåŸºæº–ï¼‰ |

**è³‡æ–™åˆ†å‰²**ï¼š
- è¡ç”Ÿé›†ï¼š75% (n=13,694)
- é©—è­‰é›†ï¼š25% (n=4,564)

**è©•ä¼°æŒ‡æ¨™**ï¼š
- AUC-ROCï¼ˆä¸»è¦æŒ‡æ¨™ï¼‰
- Sensitivity / Specificity

---

### ç¬¬ 5 é ï¼šçµæœ â€” æ¨¡å‹æ¯”è¼ƒ

| æ¨¡å‹ | é©—è­‰é›† AUC | æ’å |
|------|-----------|------|
| **Ensemble** | **0.881** | 1 â­ |
| XGBoost | 0.877 | 2 |
| Logistic Regression | 0.859 | 3 |

**é—œéµç™¼ç¾**ï¼š
- æ©Ÿå™¨å­¸ç¿’å„ªæ–¼å‚³çµ±çµ±è¨ˆï¼ˆAUC +2%ï¼‰
- Ensemble é›†æˆæ–¹æ³•æ•ˆæœæœ€ä½³
- LR ä½œç‚ºåŸºæº–ä»æœ‰ä¸éŒ¯è¡¨ç¾

---

### ç¬¬ 6 é ï¼šç‰¹å¾µé‡è¦æ€§ï¼ˆXGBoostï¼‰

| æ’å | ç‰¹å¾µ | ç›¸å°é‡è¦æ€§ |
|------|------|-----------|
| 1 | **Year(-1) CAVI æ¸¬é‡æ™‚çš„ SBP** | 100% |
| 2 | Year(-1) è¨ºæ‰€ SBP | 57.3% |
| 3 | BMI | é‡è¦ |
| 4 | Age | é‡è¦ |
| 5 | CAVIï¼ˆå¿ƒè¸è¡€ç®¡æŒ‡æ•¸ï¼‰ | é‡è¦ |

**â†’ ã€Œä¸€å¹´å‰çš„è¡€å£“ã€æ˜¯æœ€é‡è¦çš„é æ¸¬å› å­**

---

### ç¬¬ 7 é ï¼šæ–¹æ³•è«–é©—è­‰ â€” æˆ‘å€‘èˆ‡ Kanegae çš„å°ç…§

| è¨­è¨ˆå…ƒç´  | Kanegae 2020 | æˆ‘å€‘çš„ç ”ç©¶ | ä¸€è‡´æ€§ |
|---------|-------------|-----------|-------|
| **ç¸±å‘è¿½è¹¤** | âœ… 3 æ™‚é–“é» | âœ… 3 æ™‚é–“é» | âœ… |
| **Î” è®ŠåŒ–é‡ç‰¹å¾µ** | âœ… Year(-2)â†’(-1) | âœ… Delta1 | âœ… |
| **ML vs å‚³çµ±çµ±è¨ˆ** | âœ… ML å‹å‡º | âœ… é æœŸ ML å‹å‡º | âœ… |
| **æœ€ä½³é æ¸¬å› å­** | è¡€å£“ç›¸é—œ | BMI, è¡€å£“ç›¸é—œ | âœ… |

**â†’ Kanegae 2020 è­‰æ˜æˆ‘å€‘çš„æ–¹æ³•è«–è¨­è¨ˆæ˜¯æœ‰æ–‡ç»æ”¯æŒçš„ï¼**

---

### ç¬¬ 8 é ï¼šæˆ‘å€‘çš„é¡å¤–è²¢ç»ï¼ˆè¶…è¶Š Kanegaeï¼‰

| é …ç›® | Kanegae 2020 | æˆ‘å€‘çš„ç ”ç©¶ |
|------|-------------|-----------|
| **é æ¸¬ç›®æ¨™** | å–®ä¸€ç–¾ç—…ï¼ˆé«˜è¡€å£“ï¼‰ | **ä¸‰é«˜ï¼ˆå¤šä»»å‹™å­¸ç¿’ï¼‰** |
| **å¤–éƒ¨é©—è­‰** | âŒ åƒ…å…§éƒ¨é©—è­‰ | **âœ… CLSA è·¨åœ‹é©—è­‰** |
| **å¯è§£é‡‹æ¨¡å‹** | âŒ åƒ…é»‘ç›’æ¨¡å‹ | **âœ… PySR ç¬¦è™Ÿè¿´æ­¸** |
| **è·¨åœ‹æ³›åŒ–** | æ—¥æœ¬å–®ä¸€äººç¾¤ | **ç¾åœ‹ + åŠ æ‹¿å¤§** |

**â†’ æˆ‘å€‘åœ¨ Kanegae 2020 çš„åŸºç¤ä¸Šæœ‰å››é …é‡è¦æ“´å±•ï¼**

---

### ç¬¬ 9 é ï¼šç¸½çµ

**é¸æ“‡é€™ç¯‡è«–æ–‡çš„åƒ¹å€¼**ï¼š
1. **æ–¹æ³•è«–é©—è­‰**ï¼šè­‰æ˜ã€Œç¸±å‘è®ŠåŒ–é‡ç‰¹å¾µã€æ˜¯æœ‰æ•ˆçš„é æ¸¬æ–¹æ³•
2. **AUC åŸºæº–**ï¼šEnsemble é”åˆ° 0.881ï¼Œæˆ‘å€‘å¯ä»¥åƒè€ƒ
3. **è¨­è¨ˆå°ç…§**ï¼šå¹¾ä¹ç›¸åŒçš„æ™‚é–“æ¶æ§‹è¨­è¨ˆ

**æˆ‘å€‘çš„ç¨ç‰¹è²¢ç»**ï¼š
1. **å¤šä»»å‹™å­¸ç¿’**ï¼šåŒæ™‚é æ¸¬ä¸‰é«˜ï¼ˆéå–®ä¸€ç–¾ç—…ï¼‰
2. **å¤–éƒ¨é©—è­‰**ï¼šè·¨åœ‹ã€è·¨äººç¾¤çš„æ³›åŒ–é©—è­‰
3. **å¯è§£é‡‹æ€§**ï¼šPySR æä¾›é€æ˜çš„æ±ºç­–å…¬å¼
4. **Delta ç‰¹å¾µæ¶ˆè**ï¼šé‡åŒ– Î” ç‰¹å¾µçš„è²¢ç»ï¼ˆ+10% AUCï¼‰

---

## å·²å®Œæˆçš„è«–æ–‡ç­†è¨˜

1. [Paper_SMOTE_SHAP_2025.md](../02_literature/summaries/Paper_SMOTE_SHAP_2025.md)
2. [Paper_Prediabetes_TaiwanMJ_2024.md](../02_literature/summaries/Paper_Prediabetes_TaiwanMJ_2024.md) - Meeting 18 é¸å®š
3. [Paper_China_Prediabetes_Diabetes_2025.md](../02_literature/summaries/Paper_China_Prediabetes_Diabetes_2025.md) - å‚™é¸è«–æ–‡
4. [Paper_Kanegae_Hypertension_2020.md](../02_literature/summaries/Paper_Kanegae_Hypertension_2020.md) â­ **Meeting 19 é¸å®š**
